Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Many Insurers Want Single-State Medicare Part D Regions, AHIP Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Many plans believe it would be “prudent” to start with 50 regions in Medicare Advantage and the Part D program, the health plans trade group tells a Senate committee. However, Aetna, Humana and United have urged CMS to establish fewer than 50 regions.

You may also be interested in...

Medicare Stand-Alone Rx Plans Will Be Available "Everywhere," McClellan Says

CMS will set up a Part D bidding system that will get to the highest level of risk that the market will accept, Administrator McClellan says. "Smaller regions" could encourage drug plan sponsors that are unwilling to take on large capacity, he says.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says

Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts